Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
PLoS One. 2013 Apr 22;8(4):e61343. doi: 10.1371/journal.pone.0061343. Print 2013.
The aims of the present study were to elucidate a possible mechanism of kidney crystal formation by using a metabolic syndrome (MetS) mouse model and to assess the effectiveness of adiponectin treatment for the prevention of kidney crystals. Further, we performed genome-wide expression analyses for investigating novel genetic environmental changes. Wild-type (+/+) mice showed no kidney crystal formation, whereas ob/ob mice showed crystal depositions in their renal tubules. However, this deposition was remarkably reduced by adiponectin. Expression analysis of genes associated with MetS-related kidney crystal formation identified 259 genes that were >2.0-fold up-regulated and 243 genes that were <0.5-fold down-regulated. Gene Ontology (GO) analyses revealed that the up-regulated genes belonged to the categories of immunoreaction, inflammation, and adhesion molecules and that the down-regulated genes belonged to the categories of oxidative stress and lipid metabolism. Expression analysis of adiponectin-induced genes related to crystal prevention revealed that the numbers of up- and down-regulated genes were 154 and 190, respectively. GO analyses indicated that the up-regulated genes belonged to the categories of cellular and mitochondrial repair, whereas the down-regulated genes belonged to the categories of immune and inflammatory reactions and apoptosis. The results of this study provide compelling evidence that the mechanism of kidney crystal formation in the MetS environment involves the progression of an inflammation and immunoresponse, including oxidative stress and adhesion reactions in renal tissues. This is the first report to prove the preventive effect of adiponectin treatment for kidney crystal formation by renoprotective activities and inhibition of inflammation and apoptosis.
本研究的目的是阐明代谢综合征(MetS)小鼠模型中肾脏晶体形成的可能机制,并评估脂联素治疗预防肾脏晶体形成的效果。此外,我们还进行了全基因组表达分析,以研究新的遗传环境变化。野生型(+/+)小鼠没有肾脏晶体形成,而 ob/ob 小鼠的肾小管中出现晶体沉积。然而,脂联素显著减少了这种沉积。与 MetS 相关的肾脏晶体形成相关基因的表达分析确定了 259 个基因上调超过 2.0 倍,243 个基因下调低于 0.5 倍。基因本体论(GO)分析表明,上调的基因属于免疫反应、炎症和粘附分子类别,而下调的基因属于氧化应激和脂质代谢类别。与预防晶体相关的脂联素诱导基因的表达分析表明,上调和下调基因的数量分别为 154 个和 190 个。GO 分析表明,上调的基因属于细胞和线粒体修复类别,而下调的基因属于免疫和炎症反应以及细胞凋亡类别。这项研究的结果提供了令人信服的证据,证明代谢综合征环境中肾脏晶体形成的机制涉及炎症和免疫反应的进展,包括肾脏组织中的氧化应激和粘附反应。这是第一个证明脂联素治疗通过肾脏保护活性和抑制炎症和细胞凋亡预防肾脏晶体形成的预防效果的报告。